

Supplementary Methods

Plk1 Expression/Survival Analysis in ER-Positive Patient Tumours: Affymetrix HG-U133A and HG-U133PLUS2 microarray data from a total of 863 breast cancers were normalized and combined into a single data set as previously described (1). Survival analyses were restricted to patients with unambiguous treatment and survival information who had not received any chemotherapy (n=287).

1. Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, et al. Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells. *Molecular Cancer Therapeutics*. 2012;11(7):1488-99.